Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organon & Co. filings document the regulatory record for a NYSE-listed global healthcare company with Women's Health and General Medicines portfolios, including biosimilars. Form 8-K reports cover operating and financial results, company presentations, clinical or regulatory disclosures, material agreements, and other material events tied to the healthcare portfolio.
Proxy and governance filings describe board composition, executive compensation, shareholder voting matters, equity-award disclosures, and common stock registered under the Exchange Act. The filing record also includes disclosures on board and committee changes, audit committee review matters, capital structure, and exhibits filed in Inline XBRL.
Organon & Co. has entered into an Agreement and Plan of Merger to be acquired by Sun Pharmaceutical Holdings USA, Inc.; each eligible share will receive $14.00 in cash at the Effective Time. A Special Meeting to vote on the Merger Agreement is scheduled for July 23, 2026, with a Record Date of June 15, 2026.
The board recommends stockholders vote FOR the Merger Agreement and the related advisory compensation proposal. The proxy discloses a fairness opinion from Morgan Stanley and payment arrangements including a committed bridge facility of up to $12 billion; the Merger remains subject to customary conditions and regulatory approvals and is expected to close in early 2027.
Organon & Co. director Shalini Sharp reported a routine compensation grant of phantom stock units. She received 17,857.143 phantom stock units on the transaction date, each economically equivalent to one share of Organon common stock on a 1-for-1 basis at a reference value of $13.44 per unit.
Following this grant, her holdings of phantom stock units increased to 81,495.885. These units were granted under the Organon Non-Employee Director Savings Plan and are payable in cash after her termination of service as a director, in accordance with the plan’s terms. Holdings also reflect phantom stock acquired through dividend reinvestment on specified past dates.
Sequeira Ramona reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Ramona Sequeira received a grant of phantom stock units as compensation. On this Form 4, she was awarded 17,857.143 phantom stock units tied to Organon common stock at an indicated value of $13.44 per unit. Each unit is economically equivalent to one share of common stock but is payable in cash after she leaves the board, under the Organon Non-Employee Director Savings Plan. Following this grant and prior dividend reinvestments, her reported phantom stock holdings total 39,950.644 units.
Patton Cynthia M reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Cynthia M. Patton received a grant of 17,857.143 phantom stock units tied to Organon common stock. Each unit is economically equivalent to one share of common stock on a 1-for-1 basis and references a price of $13.44 per unit.
The award was made under the Organon Non-Employee Director Savings Plan and will be settled in cash after her service as a director ends, according to the plan terms. Following this grant and prior dividend reinvestment accruals, her holdings total 81,141.129 phantom stock units.
Ozuah Philip reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Philip Ozuah received a grant of 17,857.143 phantom stock units tied to Organon common stock. The award was recorded at a reference price of $13.44 per unit and increases his directly held phantom stock position to 81,141.133 units.
Each phantom stock unit is economically equivalent on a 1‑for‑1 basis to one share of Organon common stock but is payable in cash, not stock. The units were granted under the Organon Non-Employee Director Savings Plan and will be settled in cash after his service as a director ends, in line with the plan’s terms.
Leone Deborah R reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Deborah R. Leone received a grant of 17,857.143 phantom stock units linked to Organon common stock. The units were awarded at an indicated value of $13.44 per unit and are economic equivalents of common shares on a 1-for-1 basis.
The award was made under the Organon Non-Employee Director Savings Plan and will be settled in cash after she leaves the board, according to the plan’s terms. After this grant, Leone holds a total of 81,141.135 phantom stock units, including units accumulated through prior dividend reinvestment transactions. This filing reflects director compensation rather than an open-market stock purchase or sale.
LAZARUS ROCHELLE B reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Rochelle B. Lazarus received a grant of phantom stock units as compensation. The award covers 17,857.143 phantom stock units at a reference price of $13.44 per unit, each economically equivalent to one share of Organon common stock on a 1-for-1 basis.
After this grant and prior dividend reinvestment credits, Lazarus now holds a total of 81,141.135 phantom stock units. These units were granted under the Organon Non-Employee Director Savings Plan and will be settled in cash after her service as a director ends, rather than delivering actual shares.
Organon & Co. director Gayle Helene D received a grant of 17,857.143 phantom stock units on June 12, 2026, at an assigned value of $13.44 per unit. Each phantom unit is economically equivalent to one share of Organon common stock and is payable in cash under the Non-Employee Director Savings Plan after her board service ends. Following this award, her holdings total 81,141.134 phantom stock units, including units acquired through prior dividend reinvestment transactions.
Organon & Co. director Alan Ezekowitz received a grant of 17,857.143 phantom stock units on Organon common stock. The units were valued at $13.44 per unit and bring his total phantom stock holdings to 81,141.131 units. Each unit is economically equivalent to one share of Organon common stock and is payable in cash after his service as a director ends under the Organon Non-Employee Director Savings Plan. Holdings also reflect phantom stock acquired through dividend reinvestment on several prior dates.
ESSNER ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Robert Essner reported a compensation-related grant of phantom stock units. On June 12, 2026, he was awarded 17,857.143 phantom stock units at a reference value of $13.44 per unit.
Each phantom stock unit is economically equivalent to one share of Organon common stock on a 1-for-1 basis and is payable in cash after his service as a director ends, under the Organon Non-Employee Director Savings Plan. Following this award and prior dividend reinvestment transactions, his holdings total 81,141.129 phantom stock units.